Harvard Bioscience (HBIO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Harvard Bioscience (HBIO) is Neutral.

The composite score behind that read is +0.03, weighing +0.08 of bullish evidence against -0.26 bearish.

Harvard Bioscience last closed at $8.24, +1.35% on the session.

Against the IVW growth benchmark the position is +0.55% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for HBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Harvard Bioscience in the 12th percentile on return on equity, where 100 is best.

Harvard Bioscience is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $37.01M.

StockMap tracks Harvard Bioscience as the 40th largest of the 41 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 37 Neutral, 2 Moderate Outperform and 2 Moderate Underperform.

On that composite Harvard Bioscience ranks 28th of 41 in the group, against a group median of +0.06.